Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Gene Therapy Survey Seeks Info On Quality Controls & Monitoring

Executive Summary

FDA is gathering information on the state of the art in gene therapy research through a survey of clinical investigators.

You may also be interested in...



Gene Therapy Guidance Urges 15-Year Follow-Up, With Five "Close" Years

FDA's draft guidance on gene therapy studies follows the recommendations of the Biological Response Modifiers Advisory Committee in calling for 15 years of follow-up for patients

Gene Therapy Guidance Urges 15-Year Follow-Up, With Five "Close" Years

FDA's draft guidance on gene therapy studies follows the recommendations of the Biological Response Modifiers Advisory Committee in calling for 15 years of follow-up for patients

Gene Therapy Product QA Documentation May Become Key IND Element - FDA

Manufacturing quality assurance documentation could become a key component of gene therapy IND submissions, FDA Cellular & Gene Therapies Division Director Philip Noguchi, MD, suggested April 5.

Related Content

UsernamePublicRestriction

Register

LL1135424

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel